Lipaglyn 4mg Tablet is primarily used to controls high cholesterol and blood sugar levels in patients with type 2 diabetes known as diabetic dyslipidemia. It is used to treat various othert conditions, including Noncirrhotic Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), particularly in individuals with comorbidities such as obesity, Dyslipidemia, or Metabolic Syndrome.
Lipaglyn Tablet is taken orally or as required, do not misuse or overdose on these products. It is to be consumed with or without food. Consult a doctor about the recommended dosage and frequency for pregnant women & breastfeeding mothers.
Statins are the first line of treatment for dyslipidaemia. It is mainly indicated when the patient does not respond to statin therapy. Saroglitazar is the world’s first drug for treating diabetic dyslipidaemia or hypertriglyceridaemia in diabetes type II patients who do not respond to statins alone.
Lipaglyn Tablet is a peroxisome proliferator-activated receptor alpha and gamma agonist( PPAR alpha and gamma agonist). The PPAR agonist is a nuclear protein receptor responsible for regulating genes to control lipid metabolism, glucose level maintenance and inflammatory processes.
The significance of Lipaglyn Tablet is due to its treatment for dyslipidaemia which is a significant risk factor for cardiovascular disease, i.e. myocardial infarction/heart attack around the globe.